

## References

Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. *Brit J Obstet Gynecol*, 1990; 97(Aug): 690-94.

Center for Communications Programs (Population Information Program): IUDs — a new look. *Population Reports*, 1988; Series B(5).

Chi IC. Postpartum IUD insertion: Timing, route, lactation, and uterine perforation. In: Proceedings from the Fourth International Conference on IUDs, Butterworth-Heinemann: Boston, 1994; 219-27.

Chi IC. What we have learned from recent IUD studies: A researcher's perspective. *Contraception*, 1993; 48(Aug): 81-108.

Chi IC, Farr G. Review article: Postpartum IUD contraception — a review of an international experience. *Advances in Contraception*, 1989; 5: 127-46.

Chi IC, Wilkens L, Rogers S. Expulsions in immediate postpartum insertions of Lippes Loop D and copper T IUDs and their counterpart delta devices: An epidemiological analysis. *Contraception*, 1985; 32(2): 119-34.

Croxatto H, Ortiz M, Valdez E. IUD mechanisms of action. In: Proceedings from the Fourth International Conference on IUDs, Butterworth-Heinemann: Boston, 1994; 44-62.

Edelman D, Van Os W. Safety of intrauterine contraception. *Advances in Contraception*, 1990; 6: 207-17.

Edelman D, Porter C. The intrauterine device and ectopic pregnancy. *Contraception*, 1987; 36(1): 85-96.

Eren N, Ramos R, Gray R. Physicians vs. auxiliary nurse-midwives as providers of IUD services: A study in Turkey and the Philippines. *Stud Fam Plann*, 1983; 14(2): 43-47.

Farley TMM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: An international perspective. *The Lancet*, 1992; 339(Mar28): 785-88.

Farr G, Amatya R. Contraceptive efficacy of the copper T380A and the multiload Cu250 IUD in three developing countries. *Advances in Contraception*, 1994; 10: 137-49.

Farr G, Amatya R, Betancourt J, et al. Clinical performance of the TCu 380A and TCu 220 IUDs in four developing country family planning clinics. *Contraception*, 1994; 50: 417-29.

Faundes A, Telles E, Cristofolletti ML, et al. The risk of inadvertent intrauterine device insertion in women carriers of endocervical *Chlamydia trachomatis*. *Contraception*, 1998; 58(2):105-9.

Franks AL, Beral V, Cates W, et al. Contraception and ectopic pregnancy risk. *Am J Obstet Gynecol*, 1990; 163(4/part 1): 1120-23.

Hubacher D, Lara-Ricalde R, Taylor DJ, et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. *N Engl J Med*, 2001; 345:561-67.

JHPIEGO. Pocket Guide for Family Planning Service Providers. JHPIEGO: Baltimore; 1995.

JHPIEGO. IUD Guidelines for Family Planning Clinical Service Programs: A Problem-Solving Reference Manual, 2nd ed. JHPIEGO: Baltimore; 1993.

Ladipo OA, Farr G, Otolorin E, et al. Prevention of IUD-related pelvic infection: The efficacy of prophylactic doxycycline at IUD insertion. *Advances in Contraception*, 1991; 7: 43-54.

Larsson G, Milsom I, Jonasson K, et al. The long-term effects of copper surface area on menstrual blood loss and iron status in women fitted with an IUD. *Contraception*, 1993; 48(Nov): 471-80.

Lee NC, Rubin GL, Borucki R. The intrauterine device and pelvic inflammatory disease revisited: New results from the Women's Health Study. *Obstet Gynecol*, 1988; 73(1): 1-6.

Lee NC, Rubin GL, Ory HW, et al. Type of intrauterine device and the risk of pelvic inflammatory disease. *Obstet Gynecol*, 1993; 62(1): 1-6.

Lee NC. What we've learned about IUDs. *Am J Gynecol Health*, 1989; 3(3-S): 27-32.

Luukkainen T. The levonorgestrel-releasing IUD. *Brit J Fam Plann*, 1993; 19: 221-24.

Maudlin W, Segal S. IUD use throughout the world: Past, present, and future. In: Proceedings from the Fourth International Conference on IUDs, Butterworth-Heinemann: Boston, 1994; 1-10.

Morrison CS, Sekadde-Kigundu C, Sinei SK, et al. Is the intrauterine device appropriate contraception for HIV-1 infected women? *Br J Obstet Gynaecol*, 2001; 108(8): 784-90.

O'Hanley K, Huber DH. Postpartum IUDs: Keys for success. *Contraception*, 1992; 45(4): 351-61.

Ortiz ME, Croxatto HB. The mode of action of IUDs. *Contraception*, 1987; 36(1): 37-51.

Population Crisis Committee. Access to affordable contraception [chart]. Population Crisis Committee: Washington, DC; 1991.

Program for International Training in Health. Guidelines for clinical procedures in family planning: A reference for trainers, 2nd ed. INTRAH: Chapel Hill, NC; 1993.

Richardson B, Morrison C, Sekadde-Kigundu C, et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. *AIDS*, 1999; 13(15): 2091-97.

- Rivera R, Chi IC, Farr G. The intrauterine device in the present and future. *Obstet Gynecol*, 1993; 5: 829-32.
- Rivera R, Farr G, Chi IC. The copper IUD: Safe and effective. Family Health International: Research Triangle Park, NC; 1992.
- Sastrawinata S, Farr G, Prihadi S, et al. A comparative clinical trial of the TCu 380A, Lippes Loop D and multiload Cu 375 IUDs in Indonesia. *Contraception*, 1991; 44(2): 141-54.
- Shelton J. Risk of clinical pelvic inflammatory disease attributable to an intrauterine device. *Lancet*, 2001; 357(9253): 443.
- Sinei S, Morrison C, Sekadde-Kigonda C, et al. Complications of use of IUDs among HIV-1 infected women. *Lancet*, 1998; 351(9111): 1238-41.
- Sinei SKA, Schulz KF, Lamptey PR, et al. Preventing IUCD-related pelvic infection: The efficacy of prophylactic doxycycline at insertion. *Brit J Obstet Gynecol*, 1990; 97(5): 412-19.
- Sivin I. Dose and age dependent ectopic pregnancy risks with intrauterine contraception. *Obstet Gynecol*, 1991; 78(2): 291-98.
- Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 mg/day and the Copper TCu 380Ag intrauterine contraceptive devices: A multicenter study. *Fertil Steril*, 1994; 61(1): 70-77.
- Sivin I. IUDs are contraceptives, not abortifacients: A comment on research and belief. *Stud Fam Plann*, 1989; 20(6): 355-59
- Sivin I, Alvarez F, Diaz J, et al. Intrauterine contraception with copper and with levonorgestrel: A randomized study of the TCu 380Ag and levonorgestrel 20 mg/day devices. *Contraception*, 1984; 30(5): 443-56.
- Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: A seven year randomized study of the levonorgestrel 20mcg/day (LNg 20) and the copper T380 Ag IUDs. *Contraception*, 1991; 44(5): 473-80.
- Szczedrin W, Zighelboim I, Farr G, et al. Estudio comparativo del TCu 380 A y Nova T. *Rev Obstet Ginecol Venez*, 1993; 53(3): 171-75.
- The Population Council and the Program for Appropriate Technology in Health (PATH). The Copper T 380A IUD [information packet]. PATH: Seattle, Washington; 1989.
- Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: Three year's comparative experience of levonorgestrel and copper releasing intrauterine devices. *Obstet Gynecol*, 1991; 77(2): 261-64.
- World Health Organization. Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. Third edition, n.d. [pending publication]. WHO: Geneva. Available: [http://www.who.int/reproductive-health/publications/MEC\\_3/index.htm](http://www.who.int/reproductive-health/publications/MEC_3/index.htm).

World Health Organization. Mechanism of action, safety and efficacy of intrauterine devices: Report of a WHO scientific group. Technical Report Series 753. WHO: Geneva; 1987.